For the twelve months ended Sep 30, 2026, Medpace Holdings Inc. reported $2.84B of revenue and $517.83M of net income.
MEDP revenue was $716.00M in fiscal Q3 2026 (ended Sep 30, 2026), up 8.5% from a year earlier and up 1.2% from the prior quarter. For the full fiscal 2025 it was $2.53B, up 20.0% from fiscal 2024. Compound annual growth was +22.3% over 5 years and +21.6% over 10 years. It rose in each of the last 10 fiscal years. Fiscal 2025 is the highest of the 11 fiscal years on file.
MEDP net income was $137.46M in fiscal Q3 2026 (ended Sep 30, 2026), up 23.7% from a year earlier and up 13.3% from the prior quarter. For the full fiscal 2025 it was $451.12M, up 11.6% from fiscal 2024. Compound annual growth was +25.4% over 5 years. It rose in each of the last 9 fiscal years. Fiscal 2025 is the highest of the 11 fiscal years on file.
MEDP diluted EPS was $4.84 in fiscal Q3 2026 (ended Sep 30, 2026), up 25.4% from a year earlier and up 13.9% from the prior quarter. For the full fiscal 2025 it was $15.28, up 21.0% from fiscal 2024. Compound annual growth was +31.8% over 5 years.
MEDP free cash flow was $196.44M in fiscal Q3 2026 (ended Sep 30, 2026), down 16.6% from a year earlier and up 42.2% from the prior quarter. For the full fiscal 2025 it was $681.87M, up 19.2% from fiscal 2024. Compound annual growth was +24.6% over 5 years and +24.0% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 11 fiscal years on file.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.53B | $2.11B | $1.89B | $1.46B | $1.14B | $925.92M | $860.97M | $704.59M | $436.15M | $421.58M |
| Selling, general and admin | $197.56M | $180.18M | $161.35M | $131.40M | $108.42M | $92.16M | $95.25M | $75.68M | $63.36M | $61.51M |
| Operating income | $534.93M | $446.87M | $336.82M | $278.70M | $198.62M | $167.04M | $127.26M | $101.05M | $64.86M | $52.49M |
| Pre-tax income | $542.38M | $475.92M | $335.68M | $282.86M | $201.85M | $168.53M | $124.83M | $93.95M | $56.95M | $21.96M |
| Income tax | $91.25M | $71.54M | $52.87M | $37.49M | $20.00M | $23.15M | $24.39M | $20.77M | $17.82M | $8.53M |
| Net income | $451.12M | $404.39M | $282.81M | $245.37M | $181.85M | $145.38M | $100.44M | $73.19M | $39.12M | $13.43M |
| EPS, basic | $15.64 | $13.06 | $9.20 | $7.57 | $5.06 | $4.07 | $2.79 | $2.05 | $1.00 | $0.38 |
| EPS, diluted | $15.28 | $12.63 | $8.88 | $7.28 | $4.81 | $3.84 | $2.67 | $1.97 | $0.98 | $0.37 |
| Diluted shares | 29.5M | 32.0M | 31.8M | 33.7M | 37.7M | 37.7M | 37.6M | 36.9M | 39.8M | 36.3M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $497.05M | $669.44M | $245.45M | $28.27M | $461.30M | $277.77M | $131.92M | $23.28M | $26.49M | $37.41M |
| Receivables | $402.08M | $296.44M | $298.40M | $253.40M | $186.43M | $160.96M | $155.66M | $133.45M | $83.08M | $79.77M |
| Current assets | $989.62M | $1.03B | $593.83M | $333.96M | $690.91M | $473.65M | $317.03M | $178.11M | $129.97M | $133.25M |
| Goodwill | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $660.98M | $660.98M | $660.98M |
| Total assets | $1.98B | $2.10B | $1.66B | $1.35B | $1.66B | $1.39B | $1.14B | $967.93M | $950.72M | $979.11M |
| Current liabilities | $1.34B | $1.10B | $925.13M | $803.47M | $557.22M | $440.11M | $343.00M | $257.03M | $192.71M | $168.60M |
| Short-term debt | - | - | $0 | $50.00M | $0 | - | - | $0 | $16.50M | $12.38M |
| Long-term debt | - | - | - | - | - | - | $0 | $79.72M | $205.11M | $151.27M |
| Total debt | - | - | - | - | - | - | $0 | $79.72M | $221.61M | $163.64M |
| Total liabilities | $1.52B | $1.28B | $1.10B | $966.11M | $707.01M | $584.90M | $416.79M | $378.23M | $447.19M | $368.39M |
| Shareholders' equity | $459.07M | $825.54M | $558.95M | $386.39M | $952.93M | $805.78M | $726.28M | $598.86M | $509.26M | $610.71M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $713.22M | $608.82M | $433.37M | $388.05M | $263.33M | $258.68M | $201.87M | $156.58M | $97.39M | $91.73M |
| Capital expenditures | $31.36M | $36.55M | $36.65M | $36.88M | $28.27M | $31.34M | $17.91M | $16.02M | $11.72M | $13.54M |
| Free cash flow | $681.87M | $572.27M | $396.73M | $351.17M | $235.06M | $227.34M | $183.96M | $140.56M | $85.66M | $78.19M |
| Investing cash flow | -$31.14M | -$28.31M | -$34.63M | -$38.74M | -$31.36M | -$31.21M | -$19.14M | -$16.97M | -$12.24M | -$13.42M |
| Financing cash flow | -$860.39M | -$154.01M | -$182.64M | -$775.77M | -$44.45M | -$82.28M | -$73.92M | -$141.58M | -$97.83M | -$58.01M |
| Share repurchases | $917.39M | $169.87M | $144.02M | $847.85M | $62.10M | $98.27M | $0 | $0 | $155.58M | $0 |
| Stock-based compensation | $34.79M | $25.51M | $20.52M | $21.41M | $14.47M | $13.78M | $20.74M | $6.50M | $4.46M | $9.81M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 20.0% | 11.8% | 29.2% | 27.8% | 23.4% | 7.5% | 22.2% | 61.5% | 3.5% | 17.4% |
| Net income growth, YoY | 11.6% | 43.0% | 15.3% | 34.9% | 25.1% | 44.7% | 37.2% | 87.1% | 191.4% | - |
| EPS growth, YoY | 21.0% | 42.2% | 22.0% | 51.4% | 25.3% | 43.8% | 35.5% | 101.0% | 164.9% | - |
| Operating margin | 21.1% | 21.2% | 17.9% | 19.1% | 17.4% | 18.0% | 14.8% | 14.3% | 14.9% | 12.5% |
| Net margin | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% | 15.7% | 11.7% | 10.4% | 9.0% | 3.2% |
| Free cash flow margin | 26.9% | 27.1% | 21.0% | 24.1% | 20.6% | 24.6% | 21.4% | 19.9% | 19.6% | 18.5% |
| Return on equity | 98.3% | 49.0% | 50.6% | 63.5% | 19.1% | 18.0% | 13.8% | 12.2% | 7.7% | 2.2% |
| Return on assets | 22.8% | 19.2% | 17.1% | 18.1% | 11.0% | 10.5% | 8.8% | 7.6% | 4.1% | 1.4% |
| Current ratio | 0.74 | 0.93 | 0.64 | 0.42 | 1.24 | 1.08 | 0.92 | 0.69 | 0.67 | 0.79 |
| Debt to equity | - | - | - | - | - | - | 0.00 | 0.13 | 0.44 | 0.27 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $716.00M | $707.33M | $706.60M | $708.45M | $659.90M | $603.31M | $558.57M | $536.59M | $533.32M | $528.10M | $511.04M | $498.40M |
| Selling, general and admin | $51.77M | $48.10M | $47.92M | $44.92M | $48.08M | $46.66M | $57.90M | $45.43M | $49.22M | $41.45M | $44.08M | $42.51M |
| Operating income | $165.54M | $146.82M | $141.50M | $153.27M | $141.81M | $126.33M | $113.52M | $125.38M | $112.27M | $105.15M | $104.07M | $87.32M |
| Pre-tax income | $170.91M | $151.66M | $147.59M | $156.83M | $142.84M | $124.54M | $118.17M | $133.88M | $118.78M | $110.48M | $112.78M | $90.71M |
| Income tax | $33.45M | $30.30M | $23.72M | $21.70M | $31.70M | $34.28M | $3.58M | $16.86M | $22.35M | $22.13M | $10.19M | $12.41M |
| Net income | $137.46M | $121.36M | $123.87M | $135.13M | $111.14M | $90.26M | $114.59M | $117.02M | $96.43M | $88.35M | $102.59M | $78.30M |
| EPS, basic | $4.92 | $4.31 | $4.35 | $4.76 | $3.95 | $3.16 | $3.77 | $3.78 | $3.11 | $2.85 | $3.32 | $2.55 |
| EPS, diluted | $4.84 | $4.25 | $4.28 | $4.65 | $3.86 | $3.10 | $3.67 | $3.67 | $3.01 | $2.75 | $3.20 | $2.46 |
| Diluted shares | 28.4M | 28.6M | 29.0M | - | 28.8M | 29.1M | 31.2M | - | 32.1M | 32.1M | 32.0M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $705.32M | $502.69M | $652.68M | $497.05M | $285.35M | $46.33M | $441.44M | $669.44M | $656.90M | $510.89M | $407.01M | $245.45M |
| Receivables | $447.64M | $441.80M | $394.58M | $402.08M | $373.03M | $377.92M | $298.22M | $296.44M | $311.47M | $301.11M | $279.17M | $298.40M |
| Current assets | $1.25B | $1.05B | $1.14B | $989.62M | $737.28M | $520.80M | $821.44M | $1.03B | $1.03B | $872.52M | $744.90M | $593.83M |
| Goodwill | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M |
| Total assets | $2.30B | $2.06B | $2.13B | $1.98B | $1.75B | $1.57B | $1.90B | $2.10B | $2.08B | $1.92B | $1.80B | $1.66B |
| Current liabilities | $1.50B | $1.44B | $1.35B | $1.34B | $1.28B | $1.22B | $1.12B | $1.10B | $1.04B | $993.09M | $956.64M | $925.13M |
| Short-term debt | - | - | - | - | - | - | - | - | - | - | - | $0 |
| Total liabilities | $1.72B | $1.62B | $1.53B | $1.52B | $1.46B | $1.40B | $1.30B | $1.28B | $1.20B | $1.16B | $1.12B | $1.10B |
| Shareholders' equity | $584.94M | $433.86M | $598.31M | $459.07M | $293.64M | $172.35M | $593.61M | $825.54M | $881.44M | $763.60M | $671.54M | $558.95M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $216.60M | $162.01M | $151.79M | $192.65M | $246.21M | $148.53M | $125.84M | $190.67M | $149.07M | $116.40M | $152.68M | $156.40M |
| Capital expenditures | $20.16M | $23.91M | $6.81M | $4.54M | $10.71M | $6.11M | $9.99M | $7.64M | $10.54M | $12.87M | $5.50M | $9.99M |
| Free cash flow | $196.44M | $138.10M | $144.97M | $188.12M | $235.50M | $142.41M | $115.84M | $183.02M | $138.54M | $103.53M | $147.18M | $146.41M |
| Investing cash flow | -$20.14M | -$23.89M | -$6.75M | -$4.47M | -$10.66M | -$6.02M | -$9.99M | -$7.56M | -$10.49M | -$12.79M | $2.53M | -$8.00M |
| Financing cash flow | $6.50M | -$288.34M | $12.67M | $22.73M | $3.41M | -$540.56M | -$345.97M | -$168.61M | $6.27M | $666.0K | $7.66M | $1.52M |
| Share repurchases | $0 | $294.76M | $0 | $0 | $4.57M | $540.91M | $371.90M | $169.87M | $0 | $0 | $0 | $0 |
| Stock-based compensation | $7.60M | $4.35M | $4.92M | $5.62M | $6.32M | $5.95M | $16.89M | $5.89M | $11.73M | $3.59M | $4.31M | $5.17M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 8.5% | 17.2% | 26.5% | 32.0% | 23.7% | 14.2% | 9.3% | 7.7% | 8.3% | 14.6% | 17.7% | 26.5% |
| Net income growth, YoY | 23.7% | 34.5% | 8.1% | 15.5% | 15.3% | 2.2% | 11.7% | 49.5% | 36.7% | 44.7% | 40.7% | 14.0% |
| EPS growth, YoY | 25.4% | 37.1% | 16.6% | 26.7% | 28.2% | 12.7% | 14.7% | 49.2% | 35.6% | 42.5% | 41.0% | 18.3% |
| Operating margin | 23.1% | 20.8% | 20.0% | 21.6% | 21.5% | 20.9% | 20.3% | 23.4% | 21.1% | 19.9% | 20.4% | 17.5% |
| Net margin | 19.2% | 17.2% | 17.5% | 19.1% | 16.8% | 15.0% | 20.5% | 21.8% | 18.1% | 16.7% | 20.1% | 15.7% |
| Free cash flow margin | 27.4% | 19.5% | 20.5% | 26.6% | 35.7% | 23.6% | 20.7% | 34.1% | 26.0% | 19.6% | 28.8% | 29.4% |
| Current ratio | 0.83 | 0.73 | 0.85 | 0.74 | 0.57 | 0.43 | 0.73 | 0.93 | 0.99 | 0.88 | 0.78 | 0.64 |
Source: XBRL data Medpace Holdings Inc. files with the SEC, latest filing dated Oct 22, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MEDP | $2.84B | +20.4% | $517.83M | 18.2% | $18.27B |
| IQV | $17.31B | +8.8% | $1.40B | 8.1% | $44.80B |
| INCY | $6.01B | +24.9% | $403.41M | 6.7% | $24.39B |
| CRL | $3.98B | -1.2% | $40.19M | 1.0% | $16.17B |
| ICLR | $8.25B | +0.8% | $229.34M | 2.8% | $15.68B |
| ABSI | $1.56M | -62.3% | -$121.08M | -7756.4% | $1.75B |
| OABI | $40.21M | +90.6% | -$43.47M | -108.1% | $732.9M |
| NRC | $143.79M | +3.4% | $6.13M | 4.3% | $548.7M |
| MXCT | $31.05M | -13.2% | -$35.64M | -114.8% | $130.0M |